Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)

Author(s): Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS

Abstract

Analysis of 588 patients with vulvar carcinoma delineated four risk groups by the proportional hazards model. Groin node status (laterality and number positive) and lesion diameter were the only two important independent prognostic factors. The 5-year relative survival rates were 98%, 87%, 75%, and 29% for the risk group categories of minimal (negative groin nodes and lesion diameter less than or equal to 2 cm), low (one positive groin node and lesion diameter less than or equal to 2 cm or negative groin nodes and fewer than two lesions less than or equal to 8 cm diameter), intermediate (negative groin nodes and lesion diameter greater than 8 cm diameter, one positive groin node and lesion diameter greater than 2 cm, or two unilaterally positive groin nodes and lesion diameter less than or equal to 8 cm), and high (three or more positive groin nodes or two bilaterally positive groin nodes), respectively. Applying the International Federation of Gynecology and Obstetrics staging (1988) to these data discriminated risk of death (caused by recurrent vulvar cancer); the 5-year rates were 98%, 85%, 74%, and 31% for stages I, II, III, and IV, respectively. However, within International Federation of Gynecology and Obstetrics stage III there were 47 low-, 95 intermediate-, and 28 high-risk patients with relative survivals of 95%, 74%, and 34%, respectively. Overall, this assessment validates current International Federation of Gynecology and Obstetrics vulvar carcinoma staging, but further refinements are warranted in stage III.

Similar Articles

Trends in the incidence of invasive and in situ vulvar carcinoma

Author(s): Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA

New aspects of vulvar cancer: changes in localization and age of onset

Author(s): Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG

The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in southwest England (1997-2002)

Author(s): Falconer AD, Hirschowitz L, Weeks J, Murdoch J; South West Gynaecology Tumour Panel

Groin dissection practices among gynecologic oncologists treating early vulvar cancer

Author(s): Levenback C, Morris M, Burke TW, Gershenson DM, Wolf JK, et al.

A proposed glossary of terminology related to the surgical treatment of vulvar carcinoma

Author(s): Micheletti L, Preti M, Zola P, Zanotto Valentino MC, Bocci C, et al.

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers

Author(s): Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S

Carcinoma of the vulva

Author(s): Rutledge F, Smith JP, Franklin EW

Squamous carcinoma of the vulva: results of treatment, 1938 to 1976

Author(s): Benedet JL, Turko M, Fairey RN, Boyes DA

Changing trends in the surgical treatment of invasive carcinoma of the vulva

Author(s): Cavanagh D, Roberts WS, Bryson SC, Marsden DE, Ingram JM, et al.

Management of regional lymph nodes and their prognostic influence in vulvar cancer

Author(s): Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG

Squamous vulvar cancer: a clinically based individualization of treatment

Author(s): Rodolakis A, Diakomanolis E, Voulgaris Z, Akrivos T, Vlachos G, et al.

Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva

Author(s): Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, et al.

Carcinoma of the vulva

Author(s): Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HY

Changes in the management of vulval cancer

Author(s): Dhar KK, Woolas RP

Individualization of treatment for stage I squamous cell vulvar carcinoma

Author(s): Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS